Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A year in pharma and biotech R&D: Lack of large M&As leads to little change

This article was originally published in Scrip

Executive Summary

No surprises in the top 10, but the number of smaller companies involved in R&D, including a wealth of start-ups, continues on its unrelenting growth trajectory.

You may also be interested in...



Infographic – 2018 Pharma Pipeline Snapshot

Infographic examines the current status of biopharma pipelines by trial phase, company, and therapeutic areas.

GSK regains pipeline top spot

GlaxoSmithKline (GSK) has regained the crown of for the most drugs in development by a pharma company after two years of being displaced by Pfizer, despite reporting a small drop in the number of its R&D products.

A year in pharma and biotech R&D: The druggable genome lives on

A decade ago, the publication of the human genome foreshadowed an explosion in new drug targets. Those predictions now seem to have been overly optimistic.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel